Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.

JOHNSON CITY, Tenn., Jan. 13, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that, at the request of Revance Therapeutics, Inc., ("Revance") (Nasdaq: RVNC), it has extended the expiration of its cash tender offer to acquire all of the issued and outstanding shares of common stock, par value $0.001 per share ("Shares") of Revance, at a price of$3.10 per Share in cash, without interest and less any applicable tax w ...